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The aim of diagnostic accuracy studies is to evaluate how accurately a diag-
nostic test can distinguish diseased from nondiseased individuals. Depending
on the research question, different study designs and accuracy measures are
appropriate. As the prior knowledge in the planning phase is often very limited,
modifications of design aspects such as the sample size during the ongoing trial
could increase the efficiency of diagnostic trials. In intervention studies, group
sequential and adaptive designs are well established. Such designs are charac-
terized by preplanned interim analyses, giving the opportunity to stop early for
efficacy or futility or to modify elements of the study design. In contrast, in diag-
nostic accuracy studies, such flexible designs are less common, even if they are as
important as for intervention studies. However, diagnostic accuracy studies have
specific features, which may require adaptations of the statistical methods or
may lead to specific advantages or limitations of sequential and adaptive designs.
In this article, we summarize the current status of methodological research and
applications of flexible designs in diagnostic accuracy research. Furthermore,
we indicate and advocate future development of adaptive design methodology
and their use in diagnostic accuracy trials from an interdisciplinary viewpoint.
The term “interdisciplinary viewpoint” describes the collaboration of experts of
the academic and nonacademic research.
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adaptive designs, diagnostic accuracy, diagnostic studies, group sequential designs, sample size
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1 INTRODUCTION
Diagnostic tests undergo an development program including several phases.1 Lijmer et al systematically reviewed 19
schemes for phased evaluations of medical tests and concluded that evaluations of technical efficacy, diagnostic accuracy,
clinical performance, therapeutic efficacy, patient outcome, and societal aspects were common phases.2,3 By diagnostic
test, we mean any form of medical testing for diagnostic purposes, for example an entity derived from a sample (also
sometimes referred to as biomarker) or an application of a diagnostic modality (eg, a maximum standard uptake value in
positron emission tomography/computed tomography). Technical efficacy covers the technical aspects of a diagnostic test
that are evaluated in the first phase.2 These aspects comprise the applicability and the equipment, and the term clinical
performance describes how useful the diagnostic test is to deduce the its desired diagnosis.3 Hence, with a supportive
result, the clinician is able tomake amore informed diagnosis than without the diagnostic test. In this article, we focus on
diagnostic accuracy studies,which aimat assessing how reliable a diagnostic test identifies specific subgroups, eg, diseased
and nondiseased. Depending on the research question, different study designs, for instance, single-arm or parallel-arm
designs, and accuracy measures are appropriate.
Both sequential trial methodology and adaptive designs have been used for several decades in intervention studies.4-12
The “reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design”13 defines
the terms “group sequential design” and “adaptive design” and thereforemakes apparent that group sequential designs fall
within the class of adaptive designs: Sequential trials are hallmarked by preplanned interim analyses at which cumulating
data are assessed with respect to early stopping for efficacy or futility with control of the overall type I error probability
at a specified level. Adaptive clinical trial designs are characterized by preplanned interim analyses, at which planned
modifications of the study design based on accumulating study data (or any other information available at the time of any
interim analysis) are possible without undermining the trial's integrity and validity.14 In the remainder, we refer to these
flexible designs as adaptive designs with the understanding that these include (group) sequential designs. It should be
noted that monitoring of safety data by a data monitoring committee or Data safety monitoring board is usually not part
of this process but a separate issue, although some authors have advocated the use of similar stopping boundaries.15
On the one hand, adaptive designs are less common in diagnostic research. On the other hand, such flexible designs
are just as important for diagnostic accuracy studies as they are for intervention studies to increase efficiency. However,
diagnostic accuracy studies have specific features, which may require modifications of the statistical methods or lead
to advantages or limitations for the application of adaptive designs.16 For example, in general, the time between inclu-
sion and completion of the study is very short for the individual participant. Therefore, the aim of this position paper
is twofold: (1) to summarize the current status of methodology research and the use of adaptive designs in diagnostic
accuracy research and (2) to advocate future development and use of adaptive designs in diagnostic accuracy trials by
highlighting the characteristics of diagnostic research.
This work evolved from a workshop on flexible designs for diagnostic studies held in Göttingen, Germany, November
6–7, 2017.17 The paper is structured as follows: First, the design aspects and the measures of diagnostic accuracy studies
are described (see Section 2). Thereafter, in Section 3, the two main adaptive design types, namely combination tests and
the conditional error function approach, are briefly described. In the main part (Section 4), methodological research and
practical perspectives of adaptive designs for diagnostic accuracy studies are outlined. In Section 5, trial steering and data
monitoring committees and their respective roles in trial conduct are summarized. A discussion in Section 6 closes the
paper.
2 DIAGNOSTIC ACCURACY STUDIES – DESIGN ASPECTS AND MEASURES
In early diagnostic trials, the disease status is often known in advance, determined by the reference standard, leading to
a case-control study design. Diagnostic case-control designs may be applied with fairly balanced sample sizes of diseased
and nondiseased in order to gather as much information on sensitivity as on the specificity, even though a prevalence of
about 50% might not mirror the true prevalence in the target population. The aim in these studies is mainly to obtain a
rough estimate of the overall diagnostic accuracy and to define a positivity threshold. In contrast, in confirmatory diagnos-
tic trials, the disease status is often determined simultaneously to the diagnostic test(s) investigated, leading to a cohort
study design. In these studies, a consecutive recruitment within a given time frame is recommended to obtain a represen-
tative sample regarding the prevalence; then, the ratio of diseased to diseased and nondiseased reflects the prevalence in
the study population. The aim of confirmatory accuracy studies is to obtain a reliable estimate of the diagnostic accuracy
at a specific threshold.
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Another important design aspect is whether an experimental diagnostic test is compared with the reference standard
only, or whether two or more diagnostic tests under evaluation are compared with each other (based on their comparison
with the reference standard). In both scenarios estimation of a test's diagnostic accuracy requires knowledge, for each
patient, of the true disease state (defined by the reference standard) and of the results of the diagnostic tests.
The third important design aspect is only valid for studies comparing two or more tests. The standard design, which is
also recommended by the EMAguideline, is thewithin-subject design (all tests under evaluation in all patients, also called
paired design).1 However, if it is not feasible or ethically justifiable, the diagnostic tests under evaluation will be applied
in independent groups, preferentially using a randomized allocation procedure. Furthermore, it can be appropriate to
include two or more readers, which leads to a two-factorial design and entails observer agreement assessment.18
The choice of the accuracy measure depends on whether it is an early or a confirmatory diagnostic accuracy study.
Early diagnostic accuracy trials may focus on overall estimates of diagnostic accuracy of tests on a continuous or ordinal
scale, without defining a positivity threshold and considering sensitivity (true positive rate) and specificity (true negative
rate) jointly. The standard approach for this scenario is to estimate a receiver operating characteristic (ROC) curve, which
displays sensitivity versus 1 minus specificity for every possible cutoff value.19-21 The area under the curve (AUC) is a
measure for the overall diagnostic accuracy. More precisely, the AUC is “the probability that, when presented with a
randomly chosen patient with disease and a randomly chosen patient without disease, the results of the diagnostic test
will rank the patient with disease as having higher suspicion for disease than the patient without disease.”19 In general,
the AUC is equal to 0.5 for a test as useful as flipping a coin and equal to 1 for a perfect test. Sometimes, not the whole
AUC is used but a partial area (pAUC) for a specific minimum sensitivity or specificity. However, as the methodology is
the same as for the whole AUC, we focus here on assessing the AUC rather than pAUC.
If the optimal cut point has already been determined or if the result of a diagnostic test is actually dichotomous, sen-
sitivity and specificity will be both considered primary endpoints in confirmatory accuracy trials. Since both measures
represent important characteristics of a diagnostic test, they are recommended to be used on equal footing as coprimary
endpoints by the European Medicines Agency (EMA), evaluated separately.1
The positive predictive value (PPV) and the negative predictive value (NPV) as probabilities for a correct test result
among the positive or negative test results, can be included as key-secondary endpoints. A reliable estimation of the
predictive values requires either a representative sample (of the population in which the diagnostic test is intended to be
applied) or the imputation of a known prevalence (for a given population) and the estimated sensitivity and specificity
into the Bayes' formula.
Regarding the statistical hypotheses, it is necessary to distinguish between single test studies and studies for the com-
parison of two or more tests. If in single test studies the aim is not only to estimate the accuracy but to assess whether the
accuracy meets some predefined required values, hypotheses have to be formulated accordingly. For the comparison of
two ormore diagnostic tests, hypothesis tests may be of interest to assess whether the performance of one test exceeds that
of the other(s). The hypotheses can be formulated for each of the accuracy measures. However, for sensitivity and speci-
ficity as coprimary endpoints, the global null hypothesis can only be rejected if both hypotheses (regarding sensitivity and
specificity) are rejected. If two tests are compared, ideally superiority in both sensitivity and specificity is achieved. How-
ever, this is often unrealistic. Hence, noninferiority is usually required in one coprimary endpoint and superiority in the
other. In general, the hypotheses are tested using confidence intervals, and p-values are rarely used. For the comparison
of two tests, confidence intervals for the differences (or ratios) of the accuracy measures are important for a meaningful
interpretation.22,23
All different study designs described above and all mentioned accuracy measures are considered in this article. In some
special cases, other endpoints could be appropriate, eg, positive and negative percent agreement (when no reference
standard is available) or diagnostic odds ratios. However, this will not be covered in this article.
3 STATISTICAL METHODS FOR ADAPTIVE DESIGNS IN INTERVENTION
STUDIES
As mentioned in Section 1, adaptive designs are well established in intervention studies. This approach uses information
from preplanned interim analyses to either decide to stop the trial early for efficacy or futility or, more generally, tomodify
design aspects. Interim analyses can be performed in a fully blinded or in an unblindedmanner. Blinded interim analyses
are based on data pooled across treatments. As this could also be done in open trials, the latest FDA guidance on adaptive
designs refers to these as adaptations based on noncomparative data.14 For instance, there is a wide range of sample size
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reestimation procedures based on noncomparative data for various types of endpoints available.24 More recently, there has
been some interest in blinded continuous monitoring procedures which result in smaller variability of the final sample
size compared to designs with only a single reestimation.25,26 Interim analyses based on unblinded data may include
formal statistical hypothesis testing. Commonly applied adaptations include sample size adjustments, treatment (or dose)
selection, and subgroup selection or enrichment (study eligibility criteria). Thereby, adaptive trial designs can result in
more efficient clinical studies and the chance of success may be increased. For group sequential designs, we refer here
to the literature.4,27 In the following, we briefly introduce combination tests and conditional error functions as these can
be used to construct very flexible designs. We also outline how to deal with multiple hypotheses in so-called adaptive
seamless designs.
Combination tests combine the p-values based on data from different stages of a trial. To control the type I error rate,
the so-called p-clud condition must be fulfilled.28 This is, for instance, the case when the data of the stages come from
independent samples, and hypothesis tests are used that result under the null hypothesis in p-values uniformly distributed
on the interval [0, 1].12 A combination test is specified by its combination function and its boundaries for early termination
of the study. Early stopping is recommended if the p-value of the interim stage is smaller than the lower boundary or larger
than the upper boundary. In the first case, the null hypothesis can be rejected. In the second case, the null hypothesis is
not rejected, and the study is stopped due to futility. When the study is supposed to continue until the final stage, the null
hypothesis will be rejected in the final analysis if the value returned by the combination function is smaller than or equal
to the critical value.
An early proposal of a combination test is the Fisher's product test in which the p-values are multiplied with each other.
The weighted Fisher's product test performs a weighted multiplicative combination of the p-values of each trial stage.
Its usage is recommended if the sample sizes of the different stages are unequal. Hereby, stages with larger sample sizes
obtain a higher weight than those with a smaller sample size. The inverse normal combination test is based on a weighted
inverse normal combination function whereby the weights are again chosen according to the planned sample sizes of the
different stages.29 The inverse normal method is equivalent to an extension of group sequential tests by decomposing the
test statistic as a weighted sum of the stagewise statistics with preplanned weights.30
The conditional error function approach represents a further approach to define the rejection area in an adaptive
design.12 One early form is the proposal by Proschan and Hunsberger for effect-based sample size reestimation. Analo-
gous to the combination tests, the conditional error function approach is defined by the lower and upper boundaries of
the rejection region and the conditional error function. The conditional error function returns the conditional type I error
rate given the data of the first stage. Hence, the overall type I error rate is the probability to reject the null hypothesis at
the first stage plus the expected value of the conditional error function in the interval between the lower and the upper
boundaries of the rejection region.31
So far, we have only considered the situation of a single hypothesis. In adaptive seamless designs combining aspects of
different development phases such as learning about the optimal dose or population with confirmatory testing, multiple
hypotheses are considered. Control of the familywise type I error probability in the strong sense can be achieved by,
eg, using combination tests on intersection hypotheses in a closed test procedure.32-34 Considering adaptive designs for
treatment or subgroup selection, the methods and aspects of their implementation have been comprehensively described
(eg, simulation models and software) in a forthcoming manuscript.34
The combination test principle as well as the conditional error function approach can also be transferred from p-values
to confidence intervals (see for example the work of Magirr et al35 and Brannath et al36).
4 ADAPTIVE DESIGNS FOR DIAGNOSTIC ACCURACY STUDIES
In Section 3, we mentioned that interim analyses could be performed in a blinded or in an unblinded manner. In the
context of intervention studies for the comparison of two drugs, blinded interim analyses, in which treatment groups are
not identified, ensure full integrity of the trial. In diagnostic studies, the connection of the results of the diagnostic test(s)
with the outcomes of the reference standard may be blinded. For example, the prevalence can be estimated in a blinded
manner by only using the results from the reference standard. In a diagnostic trial comparing two diagnostic tests, a
blinded interim analysis could be achieved by summarizing the test results for a given reference standard (diseased or
nondiseased) pooling the results of both diagnostic tests.
In sequential intervention trials, stopping for futility or efficacy can lead to reduced costs and trial dura-
tion/development time and save further study participants from harm or provide the benefit of the new therapy earlier to
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patients outside the trial. In contrast, the results of experimental tests are typically not used to inform the care of partici-
pants in the study, so there is no additional risk of harm. Accordingly, the ethical imperative to halt a study at the earliest
time to avoid harming patients is weak unless the experimental tests have direct negative consequences themselves.
However, the advantages of completing a successful trial early remain.
The need for adaptive designs in AUC studies results from the fact that prior knowledge in the planning phase is often
very limited. Pepe et al37 described standards of study designs in pivotal diagnostic accuracy studies and mentioned plan-
ning for early termination, if appropriate. Modifications of design aspects can be motivated by the interim results or by
external reasons; examples are adaptation of the reference standard or the eligibility criteria due to slow recruitment. If
sample size reestimation is performed based on the results of the interim analysis, it can, for example, impact the point
estimate of the diagnostic accuracy, the variability of the test results, the correlation between the results of the individual
diagnostic tests (in the paired design), or the proportion of missing values.
The aim of adaptive designs for diagnostic trials with sensitivity and specificity as coprimary endpoints can be the
reestimation of different parameters. Probably, the simplest case is the blinded reestimation of the prevalence, which
requires adaptation of the overall sample size (in general in case of an overestimated prevalence), which will not affect
significance testing for sensitivity, specificity, and AUC, but may do for predictive values. In contrast, for the reestimation
of sensitivity and specificity, an unblinded interim analysis is needed. Furthermore, the reestimation of the proportion
of discordant results between several diagnostic tests can be of interest; to this end, the correlation between these two
diagnostic tests can be reevaluated. With the reestimation of these parameters, the sample size of the individual status
groups can be adapted during the study. If deemed necessary, even adjustments to the reference standard are possible,
for example, by changing individual components of a multicomponent reference standard. Another important issue is
a possible modification of the positivity threshold (of the experimental test and/or of the reference standard) during the
trial, which might be possible within adaptive seamless designs.
4.1 Methodological research
4.1.1 Adaptive designs for the AUC
Regarding group sequential designs in AUC studies without sample size reestimation or other modifications, there are
several articles (for an overview see for example38-40). To our knowledge, the first article about group sequential designs
in diagnostic research was written byMazumdar and Liu, in which the authors propose an approach based on a binormal
distribution (transferable to other distributions or nonparametric models) for the comparison of two AUCs.41
The implications of group sequential designs for comparative diagnostic accuracy trials and resulting guidelines for
practitioners were presented by Mazumdar, here with the O'Brien-Fleming stopping boundaries.42 Zhou et al presented
a nonparametric group sequential design for the comparison of two AUCs in the paired design, based on the Brownian
motion.43 Tang et al proposed two group sequential designs for paired data: a nonparametric approach using a non-
parametric family of weighted AUC statistics, and a semiparametric approach based on a proportional hazards model.44
Liu et al also used a nonparametric approach, but in a more general sense for a single AUC and the comparison of two or
more AUCs in the paired design, but also for independent groups.45 Another nonparametric approach is the sequential
conditional probability ratio test procedure for the comparison of twoAUCs.46 Koopmeiners and Feng derived the asymp-
totic properties of the sequential empirical ROC curve for case-control studies.47 To identify the optimal design (stopping
for efficacy only, for futility only, or for both) Kaizer et al suggested a loss function as decision criterion for two-stage
biomarker validation studies.48
Regarding adaptive designswith sample size reestimation, the reestimation can be performed based onnuisance param-
eters without the need to adjust for the type I error.49,50 In contrast, Tang and Liu proposed a nonparametric approach for
sample size reestimation based on the estimated difference between two paired AUCs in a group sequential design with
an error-spending function.51 Brinton et al also used the idea of an internal pilot study to correct the sample size for the
true disease prevalence and variance with a control of the type I error rate.52
4.1.2 Adaptive designs for other accuracy measures
For the comparison of ROC curves, instead of AUCs, Ye and Tang derived asymptotic properties of the sequential dif-
ferences of two empirical ROC curves at the process level.40 Dong et al addressed the optimal sampling ratio including
adaptations.53
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TABLE 1 Overview of
flexible designs for the area
under the curve (AUC) and
other accuracy measures
Method Type of analysis Design Approach
Group sequential ROC curve Paired difference36 Parametric36
AUC Single group41 Parametric37,38
Paired difference37-42,44 Semiparametric40
Unpaired difference41 Nonparametric37-42,44
Sensitivity, Single group49,50 Parametric49,50
specificity Nonparametric50
PPV, NPV Single group52-54 Parametric52,53
Nonparametric54
Adaptation of sample size AUC Paired difference41-43,45-48 Parametric45,47
Nonparametric46,48
Sensitivity, Paired difference51 Parametric51
specificity
Abbreviations: NPV, negative predictive value; PPV, positive predictive value; ROC, receiver operating characteristic.
Only a few studies were identified that dealt with adaptive designs in diagnostic trials, considering sensitivity and speci-
ficity as coprimary endpoints. Shu et al54 proposed different group sequential designs to early terminate a diagnostic phase
2 trial if both the sensitivity and specificity are either good enough or below a minimally acceptable margin. Pepe et al55
proposed a group sequential design for a diagnostic phase 2 or phase 3 biomarker study with the possibility to adjust for
bias that is caused by early stopping. Onemethod for sample size recalculation in a paired diagnostic studywith sensitivity
and specificity as coprimary endpoints was presented by McCray et al.56 They reestimated the proportion of concordant
test results via maximum likelihood estimation.
There exists some literature using group sequential designs to reevaluate the PPV and the NPV of a diagnostic test.
Koopmeiners and Feng introduced a group sequential design in a diagnostic biomarker study by deriving the asymptotic
results of the PPV and NPV curves.47 Koopmeiners et al57 used this group sequential design to decide about an early
termination of a continuous diagnostic biomarker trial due to futility. In the case of an unknownprevalence, Koopmeiners
and Feng58 as well as Tayob et al59 developed group sequential designs which can be used for the unbiased estimation
of the PPV and NPV. See Table 1 for an overview of abovementioned adaptive designs for the AUC and further accuracy
measures.
4.2 Practical perspectives
Adaptive designs are rarely utilized for clinical trials in diagnostic research. Short enrollment periods, moderate savings
in time or costs due to early stopping for success, and increased logistical complexity for executing interim analyses could
be reasons why conventional fixed designs are traditionally implemented in diagnostic clinical trials instead.
Some examples of diagnostic accuracy studies using adaptive designs were identified. Shivakumar et al60 reported the
results of an interim analysis for the diagnosis of psychological distress in elderly seeking health care, without discussion
of possible biases and type I error rate inflation. Snijder et al61 presented the results of an interim analysis of a study
about image-based ex vivo drug screening for patients with aggressive hematological malignancies. The authors did not
mention a group sequential design or adjustment of the type I error. Ghaneh et al62 applied an adaptive design for sample
size reestimation based on the correlation between the test errors (false positives and false negatives) in a multicenter,
prospective diagnostic accuracy study for the diagnosis of pancreatic cancer.
Nevertheless, as already discussed, adaptive designs in diagnostic accuracy trials may be beneficial. In the following,
an early stop for futility is presented as one potential application of adaptive trial methodology.
To illustrate, the following scenario is considered. For the approval of an assay, a confirmatory study is needed to demon-
strate that sensitivity fulfills a predefined acceptance criterion, ie, the lower limit of a two-sided 95% confidence interval
(LLCI) is at least 90%, for a point estimate of 96%. Budget constraints prohibit the conduct of a pilot study in a clinical
setting, leading to uncertainty around the assay's clinical performance. The disease prevalence is low (eg 10%), conse-
quently subject recruitment can extend over the course of several years. Sample acquisition costs are high; therefore, an
economical approach to meeting the study objectives is essential.
For this scenario, it is unlikely to reach a stop for success as the binomial distribution does not allow the effect size to
be much larger than the expected 96%. Additionally, the experimentwise type I error probability needs to be controlled at
level α. Therefore, the required sample size to attain a LLCI above 90% is close to the final sample size if the significance
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level α is evenly distributed between an interim and final analysis (97.5% confidence intervals each, Bonferroni correc-
tion). An α-spending function could be used to distribute the type I error more efficiently for this scenario (for example
implemented in the R package gsdesign by Anderson63), but for reasons of simplification, we use here the Bonferroni cor-
rection. Furthermore, the optimal timing of the interim analysis is not necessarily at half-time. However, the simplified
numerical example, with the specifications above and ignoring the random nature of the point estimate looks as follows
for three design considerations:
• Conventional fixed design. For a single cohort fixed design with an α of 5% (two-sided), a minimum of 100 true positive
cases is required to allow for a maximum of four false negatives so that the LLCI is at least 90% with a point estimate
of 96%. Assuming a disease prevalence of 10%, a total sample size (diseased and nondiseased) ofN = 1000 is necessary.
• Adaptive design stopping early for success. Using the Bonferroni correction, ie, α is evenly distributed between an interim
and final analysis, a sample size of 79 true positive cases is needed to allow for two false negatives with the minimum
LLCI of 90% (point estimate: 97.5%). However, if the performance of the assay is as expected at the interim analysis, the
study cannot be stopped for success as the sample size is not large enough to attain a LLCI of at least 90%. As a result,
a sample size of 110 for true positive cases is necessary for the final analysis to ensure a minimum LLCI of 90%. The
total sample size (diseased and nondiseased) for the study including an interim analysis would be N = 1100, meaning
10% larger than for a conventional trial without an interim analysis.
• Adaptive design stopping early for futility. If only an early stop for futility is planned, it is not necessary to adjust the
type I error for the interim analysis at 50% of the recruitment. The full α = 5% could be used for the final analysis. If
the number of false negatives is already 5 or more at 50% of the recruitment, the study could be terminated for futility,
and costs for the recruitment of the remaining 50% of patients can be saved.
This example illustrates possible applications and corresponding implications of adaptive designs in diagnostic accuracy
studies.
5 DATA MONITORING COMMITTEE
Clinical trials can have a trial steering committee (TSC) and a data monitoring committee (DMC) or data monitoring
and safety board. For more information about DMC, we refer to the relevant guidelines.64-66 This does not only apply to
intervention studies but also to diagnostic trials with patient-relevant outcomes, where the new diagnostic test may lead
to an altered therapy or has any other consequences for the participants. In contrast, in diagnostic accuracy studies, such
committees are not standard.
For fixed study designs and adaptive designs with blinded interim analysis, it may be appropriate and more efficient
to combine the TSC and the DMC into an oversight committee (OC). An OC should be established if at least one of the
following issues is present: (1) reasonable safety concerns, (2) considerable uncertainty about the assumptions for the
sample size calculation, (3) the chance of external findings influencing the current study, or (4) resource intensive (in
terms of budget and/or time). An OC should involve responsible members of the study group as well as independent
members. The task of all OCmembers regarding adaptations should be tomonitor, for example, if the new diagnostic tests
lead to an obvious and unreasonable harm for the patients. Furthermore, all OC members would be involved in blinded
interim analyses (in conducting the analyses or in discussing the results) and provide recommendations about next steps.
The next steps could be stopping for futility, sample size reestimation, or other adaptations.
All OC members can also be involved in monitoring the recruitment rate. With regard to adaptive designs with
unblinded interim analysis, the DMC should be established as an independent committee, because unblinded interim
analyses leading to sample size reestimation or other adaptations have to be performed independently of the TSC. As a
result, recommendations to the sponsor about continuing or stopping the trial (for efficacy or futility) should be made by
the DMC.
6 DISCUSSION
The evaluation of diagnostic accuracy with its inherent need for a reference standard is a characteristic phase for any
diagnostic test. As such, dedicated research into how to apply adaptive trial methodology to diagnostic trials is necessary.
Currently, group sequential techniques with the main purpose of sample size reassessment or possibly early termination
8 ZAPF ET AL.
of the trial are applied, but not routinely. Furthermore, only few reports on interim analyses without discussion of type I
error rate inflation were found. We strongly believe that the field of diagnostic research could be significantly advanced
by the more frequent implementation of adaptive designs, in particular, with options for early stopping (due to efficacy
or futility) or design modifications such as sample size reassessment. In our view, these areas are two promising fields for
futuremethodological research. For this purpose, the development of further techniques for adaptive designs in diagnostic
accuracy trials is necessary.
This paper is a timely status of the research in adaptive trial methodology based on an ad hoc literature search in
PubMed/Medline and Google Scholar performed by three authors (AZ, MS, and OG) in July 2018. The literature search
was not performed systematically. A strength of the project is that coauthors from The Netherlands, UK, Germany,
Denmark, and US, working in diagnostic research in academia, a government agency, and industry contributed.
This study is, to the best of our knowledge, the first to summarize the current status of the topic from a diagnostic
research point of view and to indicate potential future research subjects from an interdisciplinary standpoint. An inter-
disciplinary viewpoint describes the collaboration of experts of academic and nonacademic research areas, which helps
to reveal different requirements adaptive designs in diagnostic trials must maintain.
Onemay think that adaptive trial methodology can be transferred to diagnostic research because it has been established
and used for decades now.7,11 To some extent, this may be true, especially when thinking of late phase diagnostic trials
establishing patient benefit, thereby requiring randomized designs. However, diagnostic accuracy research is peculiar and
prevents a simple application of preexisting techniques.
• A reference standard is a prerequisite for any diagnostic accuracy study.
• The primary outcome is twofold (sensitivity and specificity), implying an important role on the prevalence with respect
to the achievable accuracy in parameter estimation.
• Diagnostic accuracy trials are often planned and conducted in a within-subject (or paired) design, thereby shifting the
focus on discordant pairs of results and their (dis)agreement.
• Keeping the blind regards the interim analysis, meaning the results of diagnostic test(s) and reference standard, not
randomization information with respect to study arms (as is the case in interventional research).
Tang et al argued that the use of adaptive designs in diagnostic accuracy studies is an obvious option since they are con-
ducted so fast.44 Hence, the speed of recruitment determines the applicability of a group sequential design (or in fact any
other adaptive design): the longer the length of trial recruitment, the more realistic the application of a group-sequential
design becomes.
In case of early termination of the study, risks and consequences of interim analyses with respect to possible bias need
to be taken into consideration.67-71 Our study stresses the need for continuing research into possible applications of adap-
tive designs in diagnostic accuracy research. Recent endeavors concerning late phase diagnostic trials on patient benefit,
which are beyond the focus of this study, dealt with multiplicity issues in exploratory subgroup analysis, including adap-
tive biomarker-driven designs72 and specified the application of an enrichment design comparing a new endovascular
treatmentwith standard of care for ischemic stroke patients.73 The following questionsmight be subject to future research:
• How can adaptive designs be applied with possible early stopping due to efficacy or futility as well as seamless designs?
• Can adaptive designs for the reestimation of PPV and NPV be transferred to the reestimation of the sensitivity and
specificity?
• What is the optimal time point for an interim analysis—as early as possible, or as late as necessary? First interim
analysis with 40%, 50%, or 60% of patients? This issue depends on the duration of evaluation , eg, histopathological
examination of tissue following a diagnostic test or follow-up of at least 6 months as part of a composite reference
standard.
Furthermore, this paper is limited to adaptive designs in diagnostic accuracy research, as these areas concern the very
characterization of a diagnostic test; diagnostic thinking efficacy and therapeutic efficacy focus, in opposition, on clinical
endpoints or surrogates of those for patient benefit, which, in turn, are investigated in patient outcome research later in
the process. Adaptive designs for such studies are also subject to future research.
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